← Back to Clinical Trials
Recruiting NCT06089421

NCT06089421 Genetic Information Assistant in Telegenetics

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06089421
Status Recruiting
Phase
Sponsor University of Virginia
Condition Gene Mutation-Related Cancer
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2025-04-01
Primary Completion 2027-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Genetic Information AssistantTelegenetics with UVA genetic counselor

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 96 participants in total. It began in 2025-04-01 with a primary completion date of 2027-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing? Participants will: * have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot * answer questions about their cancer genetic knowledge and how they are doing * provide a saliva sample for genetic testing to test for cancer gene mutations * have their genetic testing results provided to them. * have the option to share their genetic testing results with family members Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.

Eligibility Criteria

Inclusion Criteria: * At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged 18 and over. * Subjects must have a smartphone with access to cellular and/or internet service or a computer with internet service. * Subjects must have technological competency/proficiency to use their Smartphone and/or computer in conjunction with the communication aid GIA. Exclusion Criteria: * Cannot communicate in English or Spanish. * Subjects must not have completed panel-based cancer genetic testing in the past.

Contact & Investigator

Central Contact

Evelyn Villalobos

✉ EV4PD@uvahealth.org

📞 (434) 297-4579

Principal Investigator

Kari Ring, MD

PRINCIPAL INVESTIGATOR

University of Virginia

Frequently Asked Questions

Who can join the NCT06089421 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Gene Mutation-Related Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06089421 currently recruiting?

Yes, NCT06089421 is actively recruiting participants. Contact the research team at EV4PD@uvahealth.org for enrollment information.

Where is the NCT06089421 trial being conducted?

This trial is being conducted at Charlottesville, United States.

Who is sponsoring the NCT06089421 clinical trial?

NCT06089421 is sponsored by University of Virginia. The principal investigator is Kari Ring, MD at University of Virginia. The trial plans to enroll 96 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology